- "We are encouraged by these results that suggest that treating earlier in the disease and treating longer shows a delay in the progression of the disease," says Prosensa (RNA +28.6%) CEO Hans Schikan.
- The analysis of 96-week extension data shows a 49 meter difference between those on continual treatment and those who had been on a placebo for 48 weeks followed by active drug.
- Press release
- At the moment, the company is presenting further details of the results at the JPMorgan healthcare conference.
Prosensa flies after update on Drisapersen
Jan 16 2014, 13:17 ET